Analysis of the predictability of lung cancer using DNA Repair functional assays and cryopreserved blood samples of the PLCO prospective cohort

使用 DNA 修复功能测定和 PLCO 前瞻性队列冷冻保存的血液样本分析肺癌的可预测性

基本信息

  • 批准号:
    10641094
  • 负责人:
  • 金额:
    $ 19.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-06 至 2026-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract Elucidating the etiology of lung cancer is interwoven with the identification of risk factors for the disease, and is critical to advance prevention, and assist early detection of this lethal tumor. While smoking status and aging are well documented key lung cancer risk factors, along with several additional risk factors including certain environmental and occupational carcinogenic exposures, there is a gap in our knowledge of other important causes of the disease including biological processes that may modify the impact of exposures or be independent risk factors. Because DNA repair ability is key in avoiding mutations and preventing cancer, and likely reflects multiple inherited and other influences, we have previously developed a panel of three functional DNA repair blood tests, which directly measure an individual’s effectiveness at repairing oxidative DNA damage by the enzymes OGG1, MPG and APE1. Using these tests in a case- control study, we found that a low DNA repair score, calculated from the three tests, was strongly associated with lung cancer in addition to and independent of smoking. This was recently replicated in a second case-control study, suggesting that adding the DNA repair score to current lung cancer risk models is likely to substantially improve risk prediction. The data so far is consistent with a causative role in lung cancer, but because the findings are based on case-control studies, where disease bias cannot be ruled out, persuasive evidence to support a role of a low DNA repair score in lung cancer etiology requires demonstrating its ability to predict lung cancer in prospective cohort studies. Our goal is to examine the predictive ability of the DNA repair score for lung cancer in a nested case- control study within a prospective cohort, namely the PLCO Screening Trial. DNA repair activity will be measured in expanded T cells from PLCO pre-diagnostic cryopreserved viable whole blood samples of current smokers and never-smokers who subsequently developed lung cancer, and will be compared to samples from matched controls who did not develop any type of cancer, from which the ability to predict lung cancer can be inferred. Further, DNA repair tests will be expanded with three new functional tests for the DNA repair enzymes TDG, SMUG1 and NEIL1. Using a set of test samples received from the PLCO Trial, we have demonstrated that T cells could be effectively and efficiently expanded from whole blood samples cryopreserved for 12 or 20 years, and were suitable for measuring all six DNA repair enzyme activities, yielding reproducible values comparable to fresh lymphocytes. A successful outcome of this study will support the role of sub-optimal DNA repair of oxidative DNA damage in the etiology of lung cancer, and will facilitate the adaptation of the DNA repair score into clinically-validated biomarkers for risk assessment of lung cancer. This is expected to improve risk estimates, and provide better selection criteria for early detection of lung cancer by methods such as low-dose CT. 1
项目总结/摘要 阐明肺癌的病因与确定疾病的危险因素交织在一起, 并且对于推进预防和协助早期发现这种致命肿瘤至关重要。吸烟状态 和衰老是有据可查的肺癌的主要危险因素,沿着的还有其他几个危险因素 包括某些环境和职业致癌物暴露,我们的知识存在空白, 疾病的其他重要原因,包括可能改变疾病影响的生物过程, 风险因素或独立风险因素。因为DNA修复能力是避免突变的关键, 预防癌症,并可能反映了多种遗传和其他影响,我们以前已经开发了 一组三个功能性DNA修复血液测试,直接测量个人的有效性, 通过酶OGG 1、MPG和APE 1修复氧化DNA损伤。把这些测试用在一个案子上- 在对照研究中,我们发现,从三个测试中计算出的低DNA修复分数, 与肺癌的关系除了吸烟之外,也与吸烟无关。最近, 第二项病例对照研究表明,将DNA修复评分添加到目前的肺癌风险模型中, 很可能会大大改善风险预测。到目前为止的数据与肺中的致病作用一致 癌症,但因为研究结果是基于病例对照研究,其中疾病偏见不能排除 有说服力的证据支持低DNA修复评分在肺癌病因学中的作用, 在前瞻性队列研究中证明了其预测肺癌的能力。 我们的目标是在巢式病例中检查DNA修复评分对肺癌的预测能力- 前瞻性队列中的对照研究,即PLCO筛选试验。DNA修复活性将是 在来自PLCO诊断前冷冻保存的活全血样品的扩增T细胞中测量, 目前吸烟者和从不吸烟者随后患上肺癌,并将与 来自未患任何类型癌症的匹配对照组的样本, 肺癌的可能性很大。此外,DNA修复测试将扩大三个新的功能测试, DNA修复酶TDG、SMUG 1和NEIL 1。使用从PLCO收到的一组测试样品 试验中,我们已经证明T细胞可以有效地和高效地从全血中扩增, 冻存12年或20年的样品,适合于所有六种DNA修复酶的测定 活性,产生与新鲜淋巴细胞相当的可重复值。成功的结果 这项研究将支持氧化性DNA损伤的次优DNA修复在肺疾病病因学中的作用。 癌症,并将促进DNA修复评分适应临床验证的生物标志物的风险 肺癌的诊断预计这将改善风险估计,并提供更好的选择标准 用于通过低剂量CT等方法早期检测肺癌。 1

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ZVI LIVNEH其他文献

ZVI LIVNEH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ZVI LIVNEH', 18)}}的其他基金

DNA Repair Biomarkers for Cancer Risk & Early Detection
DNA 修复癌症风险生物标志物
  • 批准号:
    7278823
  • 财政年份:
    2005
  • 资助金额:
    $ 19.11万
  • 项目类别:
DNA Repair Biomarkers for Cancer Risk Assessment and Ea*
用于癌症风险评估和 Ea* 的 DNA 修复生物标志物
  • 批准号:
    7682865
  • 财政年份:
    2005
  • 资助金额:
    $ 19.11万
  • 项目类别:
DNA Repair Biomarkers for Cancer Risk Assessment and Ea*
用于癌症风险评估和 Ea* 的 DNA 修复生物标志物
  • 批准号:
    7122052
  • 财政年份:
    2005
  • 资助金额:
    $ 19.11万
  • 项目类别:
DNA Repair Biomarkers for Cancer Risk Assessment and Ea*
用于癌症风险评估和 Ea* 的 DNA 修复生物标志物
  • 批准号:
    7000533
  • 财政年份:
    2005
  • 资助金额:
    $ 19.11万
  • 项目类别:
DNA Repair Biomarkers for Cancer Risk Assessment and Ea*
用于癌症风险评估和 Ea* 的 DNA 修复生物标志物
  • 批准号:
    7668707
  • 财政年份:
    2005
  • 资助金额:
    $ 19.11万
  • 项目类别:
ERROR PRONE REPAIR--MUTAGENESIS AND AGING
容易出错的修复——诱变和老化
  • 批准号:
    3116153
  • 财政年份:
    1986
  • 资助金额:
    $ 19.11万
  • 项目类别:
ERROR PRONE REPAIR--MUTAGENESIS AND AGING
容易出错的修复——诱变和老化
  • 批准号:
    3116157
  • 财政年份:
    1986
  • 资助金额:
    $ 19.11万
  • 项目类别:
ERROR PRONE REPAIR, MUTAGENESIS AND AGING
容易出错的修复、诱变和老化
  • 批准号:
    3116156
  • 财政年份:
    1986
  • 资助金额:
    $ 19.11万
  • 项目类别:

相似国自然基金

靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0 万元
  • 项目类别:
    面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
  • 批准号:
    2023JJ50274
  • 批准年份:
    2023
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    33 万元
  • 项目类别:
    地区科学基金项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
  • 批准号:
    n/a
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
  • 批准号:
    81973577
  • 批准年份:
    2019
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
  • 批准号:
    81602908
  • 批准年份:
    2016
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
  • 批准号:
    81501928
  • 批准年份:
    2015
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

The Phenomenon of Stem Cell Aging according to Methylation Estimates of Age After Hematopoietic Stem Cell Transplantation
根据造血干细胞移植后甲基化年龄估算干细胞衰老现象
  • 批准号:
    23K07844
  • 财政年份:
    2023
  • 资助金额:
    $ 19.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of Age-dependent Functional Changes in Skeletal Muscle CB1 Receptors by an in Vitro Model of Aging-related Muscle Atrophy
通过衰老相关性肌肉萎缩的体外模型分析骨骼肌 CB1 受体的年龄依赖性功能变化
  • 批准号:
    22KJ2960
  • 财政年份:
    2023
  • 资助金额:
    $ 19.11万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Joint U.S.-Japan Measures for Aging and Dementia Derived from the Prevention of Age-Related and Noise-induced Hearing Loss
美日针对预防与年龄相关和噪声引起的听力损失而导致的老龄化和痴呆症联合措施
  • 批准号:
    23KK0156
  • 财政年份:
    2023
  • 资助金额:
    $ 19.11万
  • 项目类别:
    Fund for the Promotion of Joint International Research (International Collaborative Research)
The Effects of Muscle Fatigability on Gait Instability in Aging and Age-Related Falls Risk
肌肉疲劳对衰老步态不稳定性和年龄相关跌倒风险的影响
  • 批准号:
    10677409
  • 财政年份:
    2023
  • 资助金额:
    $ 19.11万
  • 项目类别:
Characterizing gut physiology by age, frailty, and sex: assessing the role of the aging gut in "inflamm-aging"
按年龄、虚弱和性别表征肠道生理学特征:评估衰老肠道在“炎症衰老”中的作用
  • 批准号:
    497927
  • 财政年份:
    2023
  • 资助金额:
    $ 19.11万
  • 项目类别:
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
  • 批准号:
    10679287
  • 财政年份:
    2023
  • 资助金额:
    $ 19.11万
  • 项目类别:
Role of AGE/RAGEsignaling as a driver of pathological aging in the brain
AGE/RAGE信号传导作为大脑病理性衰老驱动因素的作用
  • 批准号:
    10836835
  • 财政年份:
    2023
  • 资助金额:
    $ 19.11万
  • 项目类别:
Elucidation of the protein kinase NLK-mediated aging mechanisms and treatment of age-related diseases
阐明蛋白激酶NLK介导的衰老机制及年龄相关疾病的治疗
  • 批准号:
    23K06378
  • 财政年份:
    2023
  • 资助金额:
    $ 19.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Underlying mechanisms of age-related changes in ingestive behaviors: From the perspective of the aging brain and deterioration of the gustatory system.
与年龄相关的摄入行为变化的潜在机制:从大脑老化和味觉系统退化的角度来看。
  • 批准号:
    23K10845
  • 财政年份:
    2023
  • 资助金额:
    $ 19.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeting Age-Activated Proinflammatory Chemokine Signaling by CCL2/11 to Enhance Skeletal Muscle Regeneration in Aging
通过 CCL2/11 靶向年龄激活的促炎趋化因子信号传导以增强衰老过程中的骨骼肌再生
  • 批准号:
    478877
  • 财政年份:
    2023
  • 资助金额:
    $ 19.11万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了